116476-13-2

Basic information

• Product Name: SEMOTIADIL
• Synonyms: SEMOTIADIL;-2-[2-[3-[[2-(1，3-Benzodioxol-5-yloxy)ethyl]methylamino]propoxy]-5-rnethoxyphenyl]-4-methyl-2H-1，4-benzothiazin-3(4H)-one;DS-4823：SD-3211;(2R)-2α-[2-[3-[[2-(1,3-Benzodioxol-5-yloxy)ethyl]methylamino]propoxy]-5-methoxyphenyl]-4-methyl-2H-1,4-benzothiazin-3(4H)-one;(2R)-2α-[5-Methoxy-2-[3-[methyl[2-[(1,3-benzodioxol-5-yl)oxy]ethyl]amino]propoxy]phenyl]-4-methyl-2H-1,4-benzothiazin-3(4H)-one
• CAS NO: 116476-13-2
• Molecular Formula: C₂₉H₃₂N₂O₆S
• Molecular Weight: 536.646
• Mol File: 116476-13-2.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 727.3°Cat760mmHg
• Flash Point: 393.7°C
• Appearance: /
• Density: 1.263g/cm³
• Vapor Pressure: 5.23E-21mmHg at 25°C
• Refractive Index: 1.61
• CAS DataBase Reference: SEMOTIADIL(CAS DataBase Reference)
• NIST Chemistry Reference: SEMOTIADIL(116476-13-2)
• EPA Substance Registry System: SEMOTIADIL(116476-13-2)

Safety Data

• Hazardous Substances Data: 116476-13-2(Hazardous Substances Data)

Usage

General Description

I'm sorry, but "SEMOTIADIL" doesn't appear to exist in the context of chemicals nor it's related to any known substances, pharmaceuticals, or compounds. It might be a typographical error, a term from a different field, or a non-English term. Please verify the provided information or provide more context.

InChI:InChI=1/C29H32N2O6S/c1-30(14-16-34-21-10-12-25-26(18-21)37-19-36-25)13-6-15-35-24-11-9-20(33-3)17-22(24)28-29(32)31(2)23-7-4-5-8-27(23)38-28/h4-5,7-12,17-18,28H,6,13-16,19H2,1-3H3/t28-/m1/s1

Upstream product

• 93848-37-4 3,4-Dihydro-2-(2-hydroxy-5-methoxyphenyl)-4-methyl-3-oxo-2H-1,4-benzothiazine 
• 93848-31-8 2-<2-(3-chloropropoxy)-5-methoxyphenyl>-3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazine 
• 116354-42-8 N-methyl-N-<2-<3,4-(methylenedioxy)phenoxy>ethyl>amine 
• 123388-07-8 3,4-dihydro-2-<5-methoxy-2<3-ethyl>amino>propoxy>phenyl>-4-methyl-3-oxo-2H-1,4-benzothiazine 

Related news

Enantioselective protein binding of SEMOTIADIL (cas 116476-13-2) and levoSEMOTIADIL (cas 116476-13-2) determined by high-performance frontal analysis☆08/19/2019

An on-line frontal analysis HPLC system was developed for the determination of the unbound concentrations of semotiadil, a new calcium antagonist with non-dihydropyridine structure, and its antipode (levosemotiadil), and was applied to the enantioselective investigation of their plasma protein b...detailed

Photochemical localization of the SEMOTIADIL (cas 116476-13-2) binding region within the cardiac Ca2+ channel α1 subunit. Comparison with the skeletal muscle counterpart08/17/2019

We have previously identified the binding region of a new Ca2+ antagonist semotiadil in the skeletal muscle Ca2+ channel. To the same semotiadil derivatives, the cardiac counterpart showed distinct and different binding characteristics: semotiadil and its photoaffinity analog D51-4700 inhibited ...detailed

Effects of SEMOTIADIL (cas 116476-13-2) fumarate (SD-3211) on renal hemodynamics and function in dogs08/15/2019

Studies were carried out to define the effect of semotiadil on renal hemodynamics, renal function and renin release in pentobarbital-anesthetized dogs. Intrarenal arterial infusion of semotiadil resulted in a significant increase in renal blood flow (RBF), glomerular filtration rate (GFR), urine...detailed

SEMOTIADIL (cas 116476-13-2) improves survival of rats with monocrotaline-induced pulmonary hypertension: comparison with diltiazem08/14/2019

We compared the effects of semotiadil, a novel Ca2+ channel blocker, with those of diltiazem on survival and regression of right ventricular hypertrophy and media thickening of pulmonary arteries in a rat model of pulmonary hypertension. Pulmonary hypertension was induced by a single injection o...detailed

Regular ArticleAntiplatelet activity of SEMOTIADIL (cas 116476-13-2) fumarate08/13/2019

Calcium antagonists are known to exert antiplatelet activity. Semotiadil fumarate (SD-3211), a new benzothiazine, was therefore examined for its antiplatelet activity. The inhibitory activity on adenosine diphosphate (ADP)-, collagen-, arachidonic acid (AA)-, and platelet activating factor (PAF)...detailed

Relevant articles and documents

Synthesis and Ca2+ Antagonistic Activity of 2--5-methoxyphenyl>-3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazines

As an extension of the previous investigation (J.Med.Chem. 1988, 31, 919), we synthesized a series of 2-5-methoxyphenyl>-3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzothiazines (3) and evaluated their Ca2+ antagonistic activities.Ca2+ antagonistic activity was measured with isolated depolarized guinea pig taenia cecum.On the basis of their potent Ca2+ antagonistic activity, six benzothiazines were selected and further evaluated for their vasocardioselectivity.Among these six compounds, the key compound 15 ethyl>amino>propoxy>phenyl>- 4-methyl-3-oxo-2H-1,4-benzothiazine hydrogen fumarate was recognized as having the lowest cardioselectivity.Following optical resolution, the absolute configuration of the compound's optically active enantiomer was determined by means X-ray crystallography of a synthetic precursor (+)-4a.The Ca2+ antagonistic activity of 15 was found to reside primarily in (+)-15 (which was about 7 times more potent than (-)-15).The in vitro study showed that (+)-15 had a low cardioselectivity compared to verapamil and diltiazem.This result suggests that (+)-15 would exhibit less adverse effects due to cardiac inhibition than diltiazem and verapamil in therapeutic use.